# Mass Balance and Biotransformation of [14C]HSK7653 in Human

> **NCT04540016** · PHASE1 · COMPLETED · sponsor: **Sichuan Haisco Pharmaceutical Group Co., Ltd** · enrollment: 6 (actual)

## Conditions studied

- Type II Diabetes

## Interventions

- **DRUG:** [14C]HSK7653

## Key facts

- **NCT ID:** NCT04540016
- **Lead sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-15
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-21
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540016, "Mass Balance and Biotransformation of [14C]HSK7653 in Human". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04540016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*